What is the translation of " DECREASE IN CMAX " in Slovenian?

• zmanjšanje cmax
• znižanje cmax

Examples of using Decrease in cmax in English and their translations into Slovenian

There is a 49% decrease in Cmax of nateglinide in dialysis-dependent diabetic patients.
Pri sladkornih bolnikih, odvisnih od dialize, se Cmax nateglinida zniža za 49%.

The rate of absorption was affected, resulting in a 36% decrease in Cmax and an increase in Tmax by 2 hours.
Vplivalo je na hitrost absorpcije in povzročilo 36% zmanjšanje Cmax in podaljšanje Tmax za 2 uri.

There was a decrease in Cmax and AUC, and an increase in the time to reach maximum plasma concentrations when amifampridine phosphate was administered with food as compared to without food.
Prišlo je do zmanjšanja vrednosti Cmax in AUC in podaljšanja časa do doseženih največjih koncentracij v plazmi, ko se je amifampridinijev fosfat vnašal s hrano, v primerjavi z vnosom brez hrane.

Administration of TMZ with food resulted in a 33% decrease in Cmax and a 9% decrease in area under the curve(AUC).
Jemanje TMZ s hrano je povzročilo 33% zmanjšanje Cmax in 9% zmanjšanje površine pod krivuljo(AUC).

Indinavir A pharmacokinetic study with indinavir has shown a 28% decrease in AUC and a 36% decrease in Cmax for indinavir.
Indinavir Farmakokinetična raziskava z indinavirjem je pokazala 28- odstotno zmanjšanje AUC in 36- odstotno znižanje Cmax indinavirja.

Administration of TMZ with food resulted in a 33% decrease in Cmax and a 9% decrease in area under the curve(AUC).
Vnos TMZ s hrano je povzročil 33 odstotno zmanjšanje vrednosti Cmax in 9 odstotno zmanjšanje površine pod krivuljo(AUC).

Erythromycin: Concomitant use of Sinlip and erythromycin resulted in a 20% decrease in AUC(C-t) and 30% decrease in Cmax of Rosuvastatin.
Hkratna uporaba rosuvastatina in eritromicina povzroči 20-odstotno zmanjšanje AUC(0-t) in 30-odstotno zmanjšanje Cmax rosuvastatin.

Mg dose of imatinib resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment.
Miligramski odmerek imatiniba, je povzročilo zmanjšanje Cmax oziroma AUC(0-∞) za vsaj 54% oziroma 74% zadevnih vrednosti brez zdravljenja z rifampicinom.

Concomitant use of Crestor and erythromycin resulted in a 20% decrease in AUC(0-t) and a 30% decrease in Cmax of rosuvastatin.
Zaradi sočasne uporabe Crestorja in eritromicina se AUC rosuvastatina(0- t) zmanjša za 20%, Cmax pa za 30%.

Less than 20% decrease in AUC and 10% decrease in Cmax were observed in patients with mild and moderate hepatic impairment(Child-Pugh Class A and B).
Pri bolnikih z blago in zmerno okvaro jeter(Child-Pugh razreda A in B) so ugotovili manj kot 20% znižanje AUC in 10% znižanje Cmax.

Ingestion of vorapaxar with a high-fat meal resulted in no meaningful change in AUC with a small(21%) decrease in Cmax and delayed tmax(45 minutes).
Zaužitje vorapaksarja z zelo mastnim obrokom ni pomembno spremenilo AUC, je pa nekoliko(21%) zmanjšalo Cmax in podaljšalo tmax(45 minut).

The rate is decreased when given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to approximately 2.5 hours.
Hitrost absorpcije pregabalina se zmanjša, če je uporabljen s hrano; Cmax se zmanjša za približno 25- 30% in tmax se podaljša na približno 2,5 ure.

Total exposure and half-life of azithromycin were unchanged by the coadministration of fluconazole, however, a clinically insignificant decrease in Cmax(18%) of azithromycin was observed.
Splošna izpostavljenost in T½ se azitromicin s hkratno uporabo flukonazola ni spreminjal, opazili pa so tudi klinično nepomembno zmanjšanje Cmax(18%) azitromicina.

However, there is a delay in the rate of absorption characterised by a decrease in Cmax and a delay in time to peak plasma concentration(tmax).
Vendar se absorpcija upočasni, za kar je značilno zmanjšanje Cmax in podaljšan čas do najvišje koncentracije v plazmi(tmax).

Co-administration with a high-fat and high-calorie meal in healthy volunteers reduces the extent of absorption, resulting in an approximately 20% decrease in area under the concentration versus time curve(AUC) and 50% decrease in Cmax in plasma.
Sočasno dajanje z visokokaloričnim obrokom z visoko vsebnostjo maščob je pri zdravih prostovoljcih zmanjšalo obseg absorpcije, kar je povzročilo približno 20% zmanjšanje površine pod krivuljo koncentracije po času(AUC) in 50% zmanjšanje Cmax v plazmi.

In this study, administration of the chewable tablet with a high fat meal led to an average 6% decrease in AUC, 62% decrease in Cmax, and 188% increase in C12hr compared to administration in the fasted state.
V tej študiji je jemanje žvečljivih tablet z obrokom z veliko maščobami vodilo do povprečno 6% znižanja AUC, 62% znižanja Cmax in 188% zvišanja C12ur v primerjavi z jemanjem na tešče.

The rate and extent of absorption is reduced when riluzole is administered with high-fat meals(decrease in Cmax of 44%, decrease in AUC of 17%).
Hitrost in delež absorpcije se po uporabi riluzola z zelo mastnimi obroki zmanjšata(zmanjšanje Cmax za 44% in zmanjšanje površine pod krivuljo plazemskih koncentracij(AUC) za 17%).

Administration of rosiglitazone with food resulted in no change in overall exposure(AUC), although a small decrease in Cmax(approximately 20-28%) and a delay in tmax(approximately 1.75 h) were observed compared to dosing in the fasted state.
Uporaba rosiglitazona s hrano ni spremenila celotne izpostavljenosti(AUC), zabeležili pa so majhno zmanjšanje Cmax(približno 20- 28%) in zapoznitev tmax(približno 1, 75 ure) v primerjavi z uporabo na tešče.

Antacids Concomitant ingestion of an antacid containing magnesium hydroxide and aluminium hydroxide has been shown to delay absorption of febuxostat(approximately 1 hour) and to cause a 32% decrease in Cmax, but no significant change in AUC was observed.
Antacidi Pokazalo se je, da sočasno zaužitje antacida, ki vsebuje magnezijev hidroksid in aluminijev hidroksid, upočasni absorpcijo febuksostata(za približno 1 uro) in povzroči 32% znižanje Cmax, toda značilne spremembe AUC niso opazili.

Pretreatment with multiple doses of rifampicin 600 mg followed by a single 400 mg dose of imatinib resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment.
Predzdravljenje z večkratnimi odmerki rifampicina 600 mg, ki jim je sledil en 400-miligramski odmerek imatiniba, je povzročilo zmanjšanje Cmax oziroma AUC(0-∞) za vsaj 54% oziroma 74% zadevnih vrednosti brez zdravljenja z rifampicinom.

The rate and extent of absorption of metformin from Eucreas 50 mg/1000 mg were decreased when given with food as reflected by the decrease in Cmax by 26%, AUC by 7% and delayed Tmax(2.0 to 4.0 h).
Hitrost in obseg absorpcije metformina iz zdravila Eucreas 50 mg/ 1000 mg pa sta bili pri jemanju s hrano zmanjšani, kar se je odražalo na znižanju Cmax za 26%, zmanjšanju AUC za 7% in na podaljšanem Tmax(2, 0 do 4, 0 ure).

Administration of rosiglitazone with food resulted in no change in overall exposure(AUC), although a small decrease in Cmax(approximately 20% to 28%) and a delay in tmax(ca.1.75 h) were observed compared to dosing in the fasting state.
Če rosiglitazon zaužijemo s hrano, ne pride do spremembe celotne izpostavljenosti organizma(AUC), čeprav so v primerjavi z zaužitjem na tešče opazili majhno zmanjšanje Cmax(za približno 20 do 28%) in zakasnitev tmax(približno 1, 75 ure).

Against the background of strong CYP3A4 inducer rifampicin(300 mg 2 times a day for 9 days) in healthy female volunteers, a marked decrease in Cmax and AUC figures ulipristala and its active metabolite by over 90%.
Pri zdravih prostovoljcih je uporaba rifampicina, močnega induktorja CYP3A4(300 mg 2-krat/ dan, 9 dni), pokazala izrazito zmanjšanje C tmaks in AUC ulipristala in njegovega aktivnega presnovka za več kot 90%.

Administration of voriconazole did not have a significant effect on mean Cmax and AUCτ of ritonavir in the high dose study, although a minor decrease in steady state Cmax and AUCτ of ritonavir with an average of 25% and 13% respectively was observed in the low dose ritonavir interaction study.
Peroralno jemanje vorikonazola pri študiji z visokimi odmerki ni imelo pomembnega učinka na povprečna Cmax in AUCτ ritonavirja, čeprav je bilo opaziti manjše zmanjšanje Cmax in AUCτ ritonavirja v stanju dinamičnega ravnovesja za povprečno 25% oziroma 13% v študiji medsebojnega delovanja z ritonavirjem v nižjih odmerkih.

Decrease in MPA Cmax and AUC(0-12h) by 30% and 25%, respectively, were observed when CellCept was concomitantly administered with sevelamer without any clinical consequences(i.e. graft rejection).
Pri sočasnem dajanju zdravila CellCept in sevelamerja so opazili zmanjšanje Cmax mikofenolne kisline za 30% in AUC0-12h mikofenolne kisline za 25%, kliničnih posledic(zavrnitve presadka) pa ni bilo.